References
- Cervantes A, Roda D, Tarazona N, et al. (2013). Current questions for the treatment of advanced gastric cancer. Cancer Treat Rev 39:60–7
- Esposito E, Ravani L, Drechsler M, et al. (2015). Cannabinoid antagonist in nanostructured lipid carriers (NLCs): design, characterization and in vivo study. Mater Sci Eng C Mater Biol 48:328–36
- Guggenheim DE, Shah MA. (2013). Gastric cancer epidemiology and risk factors. J Surg Oncol 107:230–6
- Han Y, Li Y, Zhang P, et al. (2015). Nanostructured lipid carriers as novel drug delivery system for lung cancer gene therapy. Pharm Dev Technol 5:1–5
- Jemal A, Bray F, Center MM, et al. (2011). Global cancer statistics. CA Cancer J Clin 61:69–90
- Jin M, Shen X, Zhao C, et al. (2013). In vivo study of effects of artesunate nanoliposomes on human hepatocellular carcinoma xenografts in nude mice. Drug Deliv 20:127–33
- Joel SP, Clark PI, Heap L, et al. (1995). Pharmacological attempts to improve the bioavailability of oral etoposide. Cancer Chemother Pharmacol 37:125–33
- Johnson DH, Greco FA, Strupp J, et al. (1998). Prolonged administration of oral etoposide in patients with relapsed or refractory small cell lung cancer: a phase II trial. J Clin Oncol 8:1613–17
- Lordick F, Allum W, Carneiro F, et al. (2014). Unmet needs and challenges in gastric cancer: the way forward. Cancer Treat Rev 40:692–700
- Lorico A, Rappa G, Finch RA, et al. (1997). Disruption of the murine MRP (multidrug resistance protein) gene leads to increased sensitivity to etoposide (VP-16) and increased levels of glutathione. Cancer Res 57:5238–42
- Liu Q, Li J, Pu G, et al. (2015). Co-delivery of baicalein and doxorubicin by hyaluronic acid decorated nanostructured lipid carriers for breast cancer therapy. Drug Deliv 15:1–5
- Liu D, Liu Z, Wang L, et al. (2011). Nanostructured lipid carriers as novel carrier for parenteral delivery of docetaxel. Colloids Surf B Biointerf 2011;85:262–9
- Madane RG, Mahajan HS. (2014). Curcumin-loaded nanostructured lipid carriers (NLCs) for nasal administration: design, characterization, and in vivo study. Drug Deliv 4:1–9
- Qin L, Wang M, Zhu R, et al. (2013). The in vitro sustained release profile and antitumor effect of etoposide-layered double hydroxide nanohybrids. Int J Nanomedicine 8:2053–64
- Shao Z, Shao J, Tan B, et al. (2015). Targeted lung cancer therapy: preparation and optimization of transferrin-decorated nanostructured lipid carriers as novel nanomedicine for co-delivery of anticancer drugs and DNA. Int J Nanomedicine 10:1223–33
- Shidhaye SS, Vaidya R, Sutar S, et al. (2008). Solid lipid nanoparticles and nanostructured lipid carriers – innovative generations of solid lipid carriers. Curr Drug Deliv 5:324–31
- Sun M, Nie S, Pan X, et al. (2014). Quercetin-nanostructured lipid carriers: characteristics and anti-breast cancer activities in vitro. Colloids Surf B Biointerfaces 113:15–24
- Taratula O, Kuzmov A, Shah M, et al. (2013). Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA. J Control Release 171:349–57
- Tiwari R, Pathak K. (2011). Nanostructured lipid carrier versus solid lipid nanoparticles of simvastatin: comparative analysis of characteristics, pharmacokinetics and tissue uptake. Int J Pharm 415:232–43
- Wang J, Zhu R, Sun X, et al. (2014). Intracellular uptake of etoposide-loaded solid lipid nanoparticles induces an enhancing inhibitory effect on gastric cancer through mitochondria-mediated apoptosis pathway. Int J Nanomedicine 9:3987–98
- Zhang Z, Niu B, Chen J, et al. (2014). The use of lipid-coated nanodiamond to improve bioavailability and efficacy of sorafenib in resisting metastasis of gastric cancer. Biomaterials 35:4565–72